Literature DB >> 18209014

Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours.

R Bettini1, L Boninsegna, W Mantovani, P Capelli, C Bassi, P Pederzoli, G F Delle Fave, F Panzuto, A Scarpa, M Falconi.   

Abstract

BACKGROUND: Non-functioning pancreatic endocrine tumours (NF-PETs) are an aggressive gastroenteropancreatic neoplasm. The present study assessed survival, value of World Health Organisation (WHO) classification and prognostic utility of clinicopathological parameters at diagnosis. PATIENTS AND METHODS: From 1990 to 2004, 180 patients with NF-PETs were entered in a prospective database, and predictors of prognosis were tested in uni- and multivariate models.
RESULTS: There were 25 (14%) benign lesions, 38 (21%) neoplasms of uncertain behaviour, 100 well-differentiated carcinomas (56%) and 17 poorly differentiated carcinomas (9%). Radical resection was possible in 93 cases (51.6%). Overall 5-, 10- and 15-year survival rates were 67%, 49.3% and 32.8%, respectively, and were significantly higher in radically resected patients (93%, 80.8% and 65.2%, respectively; P < 0.00001). By multivariate analysis, poor differentiation [hazard ratio (HR) 7.3; P = 0.0001], nodal metastases (HR 3.05; P = 0.02), liver metastases (HR 3.29; P = 0.003), K(i)-67 >5% (HR 2.5; P = 0.012) and weight loss (HR 3.06; P = 0.001) were significantly associated with mortality.
CONCLUSION: This study confirms the good long-term survival of patients with NF-PETs and the prognostic value of WHO classification, liver metastases, poor differentiation, Ki-67, nodal metastases and weight loss. These latter two parameters have a prognostic value similar to that of liver metastases and Ki-67.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18209014     DOI: 10.1093/annonc/mdm552

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  65 in total

1.  Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.

Authors:  Davide Campana; Gianfranco Delle Fave; Massimo Falconi; Paola Tommassetti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01       Impact factor: 9.236

2.  Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series.

Authors:  Riccardo Casadei; Claudio Ricci; Raffaele Pezzilli; Davide Campana; Paola Tomassetti; Lucia Calculli; Donatella Santini; Nicola Antonacci; Francesco Minni
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

3.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

4.  Surgical resection and multidisciplinary care for primary and metastatic pancreatic islet cell carcinomas.

Authors:  Shaun McKenzie; Wendy Lee; Avo Artinyan; Brian Mailey; Alessio Pigazzi; Joshua Ellenhorn; Joseph Kim
Journal:  J Gastrointest Surg       Date:  2010-05-18       Impact factor: 3.452

5.  Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.

Authors:  Samer Ezziddin; Feras Khalaf; Maria Vanezi; Torjan Haslerud; Karin Mayer; Abdullah Al Zreiqat; Winfried Willinek; Hans-Jürgen Biersack; Amir Sabet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-07       Impact factor: 9.236

6.  High pre-operative fasting blood glucose levels predict a poor prognosis in patients with pancreatic neuroendocrine tumour.

Authors:  Yitao Gong; Zhiyao Fan; Pin Zhang; Yunzhen Qian; Qiuyi Huang; Shengming Deng; Guopei Luo; He Cheng; Kaizhou Jin; Quanxing Ni; Xianjun Yu; Chen Liu
Journal:  Endocrine       Date:  2020-08-29       Impact factor: 3.633

7.  Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.

Authors:  Tetsuhide Ito; Hironobu Sasano; Masao Tanaka; R Yoshiyuki Osamura; Iwao Sasaki; Wataru Kimura; Koji Takano; Takao Obara; Miyuki Ishibashi; Kazuwa Nakao; Ryuichiro Doi; Akira Shimatsu; Toshirou Nishida; Izumi Komoto; Yukio Hirata; Kazuhiko Nakamura; Hisato Igarashi; Robert T Jensen; Bertram Wiedenmann; Masayuki Imamura
Journal:  J Gastroenterol       Date:  2010-02       Impact factor: 7.527

8.  Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.

Authors:  Davide Campana; Gabriele Capurso; Stefano Partelli; Francesca Nori; Francesco Panzuto; Domenico Tamburrino; Giulia Cacciari; Gianfranco Delle Fave; Massimo Falconi; Paola Tomassetti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-26       Impact factor: 9.236

Review 9.  [Indications and operative procedures for neuroendocrine liver metastases].

Authors:  T J Musholt; H Lang
Journal:  Chirurg       Date:  2009-02       Impact factor: 0.955

10.  Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy.

Authors:  Su-Jung Kim; Jin Won Kim; Sae-Won Han; Do-Youn Oh; Se-Hoon Lee; Dong-Wan Kim; Seock-Ah Im; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang
Journal:  BMC Cancer       Date:  2010-08-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.